Rossmore Private Capital Increases Holdings in Eli Lilly and Company (NYSE:LLY)

Rossmore Private Capital boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,148 shares of the company’s stock after purchasing an additional 34 shares during the period. Eli Lilly and Company comprises approximately 2.1% of Rossmore Private Capital’s investment portfolio, making the stock its 9th biggest position. Rossmore Private Capital’s holdings in Eli Lilly and Company were worth $16,964,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Simmons Bank lifted its holdings in shares of Eli Lilly and Company by 1.5% in the third quarter. Simmons Bank now owns 8,409 shares of the company’s stock worth $7,450,000 after acquiring an additional 121 shares during the last quarter. Haverford Trust Co boosted its holdings in shares of Eli Lilly and Company by 0.9% during the 3rd quarter. Haverford Trust Co now owns 3,515 shares of the company’s stock valued at $3,114,000 after acquiring an additional 31 shares in the last quarter. Empower Advisory Group LLC grew its position in Eli Lilly and Company by 4.3% during the 3rd quarter. Empower Advisory Group LLC now owns 139,274 shares of the company’s stock worth $123,388,000 after acquiring an additional 5,682 shares during the last quarter. Moser Wealth Advisors LLC increased its holdings in Eli Lilly and Company by 40.0% in the 3rd quarter. Moser Wealth Advisors LLC now owns 455 shares of the company’s stock worth $403,000 after purchasing an additional 130 shares in the last quarter. Finally, Carrera Capital Advisors bought a new position in Eli Lilly and Company in the third quarter valued at about $244,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 1.6 %

Eli Lilly and Company stock opened at $818.79 on Wednesday. The company has a market capitalization of $777.29 billion, a PE ratio of 88.52, a PEG ratio of 3.15 and a beta of 0.43. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53. The firm’s fifty day moving average is $891.02 and its 200 day moving average is $870.71. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The company had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. Eli Lilly and Company’s revenue for the quarter was up 20.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.10 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 13.21 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.64%. Eli Lilly and Company’s payout ratio is currently 56.22%.

Wall Street Analysts Forecast Growth

LLY has been the subject of several recent research reports. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Barclays decreased their price target on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Citigroup raised their target price on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Friday, October 25th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $1,106.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Four equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,008.41.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.